Lung adenocarcinoma is a common histologic type of lung cancer with a high death rate globally. Increasing evidence shows that long non-coding RNA H19 (lncRNA H19) and CDH1 methylation are involved in multiple tumours. Here, we tried to investigate whether lncRNA H19 or CDH1 methylation could affect the development of lung adenocarcinoma. First, lung adenocarcinoma tissues were collected to detect CDH1 methylation. Then, the regulatory mechanisms of lncRNA H19 were detected mainly in concert with the treatment of overexpression of lncRNA H19, siRNA against lncRNA H19, overexpression of CDH1 and demethylating agent A-5az in lung adenocarcinoma A549 cell. The expression of lncRNA H19 and epithelial-mesenchymal transition (EMT)-related factors as well as cell proliferation, sphere-forming ability, apoptosis, migration and invasion were detected. Finally, we observed xenograft tumour in nude mice so as to ascertain tumorigenicity of lung adenocarcinoma cells.
| INTRODUC TI ON
Lung adenocarcinoma, a frequently occurring subtype of lung cancer, contributes to more than one million deaths on an annual basis globally.
1 Lung adenocarcinoma is characterized by a heterogeneous group of tumours stemming from the smaller airways and occurring in peripheral lung tissues. 2, 3 Metastasis, considered as a leading lethal cause of lung adenocarcinoma, can occur, only within months of diagnosis, in diverse organs in a swift manner. 4, 5 Major therapies for lung adenocarcinoma conclude the use of erlotinib and gefitinib. 6 However, unfortunately, lung adenocarcinoma is highly refractory to conventional radio-and chemotherapies, which poses a challenge to the treatment efficacy. 7 Emerging evidence has reported the implication of long-chain non-coding RNAs (lncRNAs) in the development as well as progression of lung cancer.
8
LncRNA H19, being an affluent and conserved transcript in the development of mammalian, is found in embryonic as well as extra-embryonic cell lineages. 9 Highly expressed lncRNA H19 was found to be responsible for metastasis of lung adenocarcinoma and to exhibit a negative correlation with the prognosis of patients with lung adenocarcinoma. 10 Moreover, a recent study has demonstrated that lncRNA H19 promotes epithelial-mesenchymal transition (EMT), a crucial process of cancer metastasis, by targeting miR-484 in human lung cancer cells. 11, 12 CDH1, a cell adhesion molecule also called E-cadherin, plays a critical part in epithelial phenotype maintenance and functions as a gene that can suppress invasion. 13 DNA methylation is considered to be a common event in lung cancer. 14 As previously reported, silencing of CDH1 gene caused by hypermethylation of its promoter aided in the occurrence of lung primary adenocarcinoma. 15 Intriguingly, lncRNA H19 was reported to inhibit the expression of E-cadherin in bladder cancer and tongue squamous cell carcinoma. 16, 17 From all the records mentioned above, it has been suggested that lncRNA H19
and CDH1 might be associated with the progression of lung adenocarcinoma. We downloaded lncRNA H19 expression in lung adenocarcinoma from the Cancer Genome Atlas (TCGA) database and found that compared with normal control tissues, lncRNA H19
was highly expressed in tissues of lung adenocarcinoma. Herein, we conducted this study to explore the effects of lncRNA H19 and CDH1 on lung adenocarcinoma with the involvement of methylation of CDH1, with the hope to raise the life quality of patients with lung adenocarcinoma.
| MATERIAL S AND ME THODS

| Ethics statement
This research study was conducted with the approval of the ethics committee of the First Hospital of Qinhuangdao. All patients participating in the study were provided with informed consent documentation, which they all subsequently signed. The animal experiment procedures were performed in accordance with strict protocols approved by the Institutional Animal Care and Use Committee.
| Study patients
This study included 60 patients (aged 
| Vector construction
siRNA single-stranded oligonucleotide fragments (Sequences:
siRNA-1:5′-TGACGGCGAGGACAGAGGAG-3′, 5′-CCCAGAGGGCAG CCATAGTG-3′; siRNA-2:5′-CCCACAACAUGAAAGAAACTT-3′, 5′-A UUUCUUUCAUGUUGUGGGrl-3′; siRNA-3:5′-GCUAGAGGAACCA GACCUUTT-3′, 5′-AAGGUCUGGUUCCUCUAGCTT-3′) and negative control (NC) si-NC sequence (5′-ACAGAGCCTCGCCTTTGCCGAT-3′, 5′-CTTGCACATGCCGGAGCCGTT-3′) were designed and synthesized based on human nucleotide lncRNA H19 sequences using shRNA online design system http://rnaid esigner. invitrogen. com/ rnaiexpress/ (Invitrogen). The siRNA fragments were then dissolved by ddH 2 O into 100 μmol/L. After that, pairwise complementary single strands (5 μL for each) were selected, mixed and annealed.
Next, four siRNA fragment mixtures were heated at 95°C for 5 minutes and then cooled at room temperature for 20 minutes to form double-stranded fragments. The annealed double-stranded siRNA was further diluted into 10 μmol/L concentration, after which the double-stranded siRNA fragments were inserted into the siRNA expression vector pGFP-V-RS using a vector construction kit for connection at room temperature for 30 minutes, and the siRNA expression plasmid was constructed. Finally, the siRNA expression plasmid was converted to the competent cell DH5a, and three clones were selected in each conversion plate, respectively, for gene sequencing in order to verify whether the inserted fragment sequences in the recombinant clones were consistent with the designed siRNA oligonucleotide sequences. CDH1 overexpression vector was constructed as follows: Complete sequence analysis of the coding region of CDH1 was performed to detect whether there was a particularly complicated secondary structure and repetitive sequences in the CDH1 gene. Subsequently, based on the analysis results of gene sequencing, CDH1 single-stranded oligonucleotide fragments were designed and synthesized, and restriction enzyme sites were added to the ends of the CDH1 sequence. PCR was used to splice the synthesized single-stranded oligonucleotide fragments into a complete gene, after which the synthesized sequences were loaded into the pGFP-V-RS vector and converted into the competent cell DH5a. Next, gene sequencing was performed so as to verify whether the inserted fragment sequences in the recombinant clones were consistent with the requirements. The mutation sites in the gene sequences were repaired by overlapping PCR. Full-length fragments after repair then underwent enzyme digestion by Xho I and EcoR and were connected to the target vector and converted into competent cell DH5a. Finally, sequence information of the target gene fragments in the recombinant clones was verified using sequencing to obtain correct CDH1 overexpression vector.
The siRNA interference vector and CDH1 overexpression vector were transiently cotransfected: Cells were seeded into each well of the 6-well plate (5 × 10 5 cells/well), followed by culturing overnight, with the cell growth observed. When the cell confluence reached approximately 80%, cell transfection was conducted. Serum-free
Opti-MEM was used to wash the cells twice, and 1.5 mL Opti-MEM was added. Next, 250 μL Opti-MEM was used to dilute 3 μg interference plasmid and NC plasmid, respectively, followed by slight mixing and addition of 1 μg overexpression vector. A total of 10 μL 
| Methylation-specific polymerase chain reaction (MSP) assay
Lung adenocarcinoma cancer tissues and adjacent tissues (each n = 60) were collected. Initially, the tissue DNA was extracted by conventional phenol-chloroform-isoamyl alcohol method and the concentration and purity of DNA were determined using ultraviolet spectrophotometry. Next, DNA modification and purification were performed with hydroquinone and sodium bisulfite (Sigma-Aldrich, SF) and DNA Clean-up System (Promega). Methylation-specific PCR reaction was as follows: The reaction system was 25 μL, including 2 μL sample DNA, 2.5 μL 10 × PCR buffer, 0.5 μL forward primer and 0.5 μL reverse primer, 2 μL dNTP, 0. 
| Immunohistochemistry
The specimens were fixed with formaldehyde for more than 
| RT-qPCR
The total RNA of cells was extracted using one-step method with ref- The experiment was repeated three times independently. The aforementioned method was equally applicable to the mRNA determination among the cells.
| Western blot analysis
The obtained tissue specimens were ground into homogenate Abbreviations: Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma/ lewkmia-2; CDH1, E-cadherin; F, forward; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; lncRNA H19, long non-coding RNA H19; PCNA, proliferating cell nuclear antigen; R, reverse; RT-qPCR, reversetranscription -quantitative polymerase chain reaction.
Chinese Academy of Sciences) were routinely cultured, detached and centrifuged, suspended and seeded in a 6-well plate. Upon cell confluence of 80%, DNAs were extracted from all the above lung adenocarcinoma cell lines. The previously designed PCR primers for CDH1 methylation and non-methylation were used to determine DNA methylation level of CDH1 using MSP assay. 
| Cell counting kit (CCK)-8 assay
Cell proliferation was detected using CCK-8 (GM-040101-5, Dojindo
Laboratories) based on its protocol. Cells in logarithmic growth after transfection were collected, rinsed with PBS, treated with trypsin, washed with additional PBS and suspended. After the cell concentration was adjusted to 5 × 10 3 cells/μL, the cells were transferred to a 96-well plate, with six duplicated wells set for each group. The plate was then placed in a 37°C incubator with 5% CO 2 in which the cells were cultured for consecutive 2 days. At the last 4 hours, 10 μL CCK-8 solution was added to each well for further culturing, after which spectrophotometer (UV-1800A, Macylab) was employed to measure OD value at the wavelength of 450 nm based on the following formula: OD = OD experiment well -OD bank well . The experiment was repeated three times.
| Sphere-forming assay
Human lung adenocarcinoma A549 cell line in each group underwent sphere-forming culture. With the addition of high glucose DMEM and 10% FBS, the A549 cells after amplification transfection were cultured in vitro in a 37°C thermostat with 5% CO 2 . When the cell confluence reached 80%, 0.25% trypsin was used to treat the cells, which were then collected, suspended and counted. Next, the cells were seeded in a 6-well ultra-low attachment plate and cultured in a 37°C incubator with 5% CO 2 . After 6 days of culturing, the tumour spheres grew into 50 μm and the cell suspension was col- 
| Flow cytometry
| Scratch test
| Transwell assay
| Immunofluorescence assay
At one week after plasmid in each group was transfected into A549 
| Chromatin immunoprecipitation (ChIP)
A ChIP kit (Merck Millipore) was used to study the enrichment of DNA methyltransferase 1 (DNMT1) and DNA methyltransferase 3A (DNMT3A) in the promoter region of CDH1 gene. A549 cells were collected, fixed in 1% formaldehyde at room temperature for 10 minutes, randomly cracked through ultrasonic treatment after 15 cycles of cross-linking (10 seconds each ultrasonic, with an interval of 10 seconds) and centrifuged at 30237 g at 4°C. The supernatant was collected and separately placed into three tubes,
followed by respective addition of NC antibody, namely, IgG of normal mice and specific rabbit antibodies of target protein, DNMT1
(1:100; ab13537, Abcam Inc) and DNMT3A (1:100; ab2850, Abcam Inc) and incubation at 4°C overnight. Following a short centrifugation, the supernatant was discarded and the non-specific complex was washed, followed by cross-linking at 65°C overnight. DNA fragments were retrieved using phenol-chloroform extraction and purification. Specific primers of the CDH1 promoter region (forward primer: 5′-AGTCCCACAACAGCATAGGG-3′; reverse primer:
5′-TTCTGAACTCAGGCGATCCT-3′) were used to test the binding of DNMT1 and DNMT3A to CDH1 promoter region.
| Luciferase reporter gene assay
The relationship between lncRNA H19 and CDH1 was detected using luciferase reporter gene assay. Based on the binding sequence between the sequence of CDH1 promoter and lncRNA H19, the wild target sequence (CDH1 wt) and mutation sequence (CDH1 mut) were designed and chemosynthesized. The restriction sites Xho I and Not I were supplemented to the ends of the sequences, and the synthesized segments were cloned to the PUC57 vector. Following positive cloning and recombinant plasmid identification using DNA sequencing, the segments were subcloned to the psi-CHECK-2 vector and transferred to the coli DH5α cells, fol- We determined methylation of CDH1 in 60 cases of lung adenocarcinoma tissues and 60 cases of adjacent tissues using MSP assay.
| Statistical analysis
No methylation of CDH1 was detected in all the 60 adjacent tissues, while among the 60 lung adenocarcinoma tissues, 17 cases showed methylation of CDH1 promoter, accounting for 28.33%. Compared with the adjacent tissues, the lung adenocarcinoma tissues exhibited a notable increase in methylation of CDH1 promoter ( Figure 1D , Table 2 ). The aforementioned results suggest that methylation of CDH1 promoter is correlated with the occurrence of lung cancer.
| A549 cell line is selected for cell transfection with silencing and overexpression plasmids of CDH1 successfully constructed
We performed RT-qPCR ( Figure 2A ) and Western blot analysis siRNA-3, oe-NC and oe-CDH1 groups was over 70% ( Figure 3B ).
Next, we further determined the expressions of lncRNA H19 and CDH1 using RT-qPCR. In comparison with the si-NC group, the siRNA-1, siRNA-2 and siRNA-3 groups had significantly reduced lncRNA H19 expression and the lowest lncRNA H19 expression was found in the siRNA-3 group among the four groups, with an inhibitory efficiency more than 70%. Therefore, siRNA-3 was selected for further experimentation. The oe-CDH1 group had a higher CDH1 mRNA expression than the oe-NC group ( Figure 3C ). Based on the results of Western blot analysis, the expression of CDH1 in the oe-CDH1 group significantly increased compared with the oe-NC group (P < .05) ( Figure 3D ). These results reveal that silencing and overexpression plasmids of CDH1 are successfully constructed. , and the lower right quadrant identifies the early apoptotic cells (annexin V+/PI-); G, expression of Bax, Bcl-2 and cleaved caspase-3 determined by Western blot analysis. lncRNA H19, long non-coding RNA H19; CDH1, E-cadherin; CCK-8, cell counting kit-8; PI, propidium iodide; PCNA, proliferating cell nuclear antigen; Bcl-2, B-cell lymphoma/lewkmia-2; Bax, Bcl-2-associated X protein; NC, negative control; DMSO, dimethylsulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *P < .05 vs the oe-NC group; # P < .05 vs the DMSO group; & P < .05 vs the si-NC group. The measurement data are presented as mean ± standard deviation, analysed by one-way analysis of variance. n = 3. The experiment was independently repeated three times 
|
| Silencing of lncRNA H19 inhibits methylation of CDH1
We downloaded lncRNA H19 expression in multiple cancers from the TCGA database and found that compared with normal tissues, lncRNA H19 was highly expressed in tissues of lung adenocarcinoma ( Figure 6A ). We designed probe primers of lncRNA H19, followed by FISH experiment ( Figure 6B For further verification, we performed ChIP assay ( Figure 6G ).
After incubation with DNMT1 and DNMT3A antibodies, the results
showed that the expression of lncRNA H19 and the expression of CDH1 promoter region in the DNMT1 and DNMT3A groups were significantly higher than those in the IgG group. LncRNA H19 induced DNMT1 and DNMT3A, which were enriched around the CDH1 promoter, to promote the methylation of CDH1.
Taken together, silencing of lncRNA H19 could inhibit methylation of CDH1. 
| D ISCUSS I ON
Lung adenocarcinoma is a major contributor to cancer-related death all over the world. 3 LncRNAs are considered as biomarkers as well as molecular targets for cancer therapies. 18 In this study, we investigated the role of lncRNA H19 and CDH1, methylation of CDH1 in lung adenocarcinoma and found that in contrary to CDH1, lncRNA F I G U R E 6 RNA-FISH and CHIP reveal that silencing of lncRNA H19 inhibits methylation of CDH1. A, expression of H19 in lung adenocarcinoma tissues and normal tissues retrieved from the TCGA database; B, subcellular localization of lncRNA H19 detected by RNA-FISH. C, CpG island in the CDH1 promoter region based on the Meth Primer software; D, the binding site between lncRNA H19 and CDH1 promoter predicted by biological website; E, the luciferase intensity of the CDH1 wild-type promoter region detected by luciferase reporter gene; F, the luciferase intensity of the M-CDH1 determined by luciferase reporter gene; G, statistical chart of CHIP. lncRNA H19, long noncoding RNA H19; CDH1, E-cadherin; NC, negative control; DMSO, dimethylsulfoxide; RNA-FISH, RNA fluorescence in situ hybridization; ChIP, chromatin immunoprecipitation; M-CDH1, methylated CDH1; DNMT1, DNA methyltransferase 1; DNMT3A, DNA methyltransferase 3A; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *P < .05 vs the NC group; # P < .05 vs the IgG group. The measurement data are presented as mean ± standard deviation, analysed by Student's t test. n = 3. The experiment was independently repeated three times At first, we found that lncRNA H19 and methylation of CDH1
were highly expressed in lung adenocarcinoma tissues compared with the normal adjacent tissues, while CDH1 expression was re- 24 In line with our study, a previous study conducted by Nakata et al reported that patients with non-small-cell lung carcinoma who showed poorly expressed CDH1 and elevated level of CDH1 methylation suffered from a poorer prognosis in comparison with those who did not. 25 Moreover, DNA methylation of CDH1 was found to be aberrantly expressed in rats with lung adenocarcinoma, 26 which was consistent with the present study.
One of the key findings of our study was that silencing of lncRNA which lncRNA H19 has been found to be able to regulate EMT, thereby affecting tumour cell metastasis. 30 Overexpression of lncRNA H19 is responsible for tumorigenesis and progression of diverse cancer types; lncRNA H19, serving as a microRNA sponge, could accelerate the process of EMT in colorectal cancer. 31 Moreover, lncRNA H19 stimulated invasion and migration of let-7 in pancreatic ductal adenocarcinoma, in part through the up-regulation of HMGA2-mediated EMT. 32 The above reports all supported our results that overexpressed lncRNA H19 could accelerate the development of lung adenocarcinoma cells, while by silencing of lncRNA H19, this trend could be significantly reversed. CDH1 is considered as an anti-oncogene in interactions between epithelial cells. 33 Reduced CDH1 expression is referred to as a biomarker for cancer invasion as well as metastasis. 34 DNA methylation is one of the epigenetic changes that account for aberrant regulation of tumour-related genes, which can affect cellular activities such as cell proliferation, apoptosis and metastasis. 35 Consistent with our results, inhibition of CDH1, identified as a critical gene during EMT process, was found to aid in tumour metastasis of breast cancer. 36 Therefore, it has been suggested that lncRNA H19 might affect cellular processes of lung adenocarcinoma cells by regulating methylation of CDH1.
Furthermore, we found that silencing of lncRNA H19 could inhibit methylation of CDH1 promoter in lung adenocarcinoma. Accumulating evidence demonstrates that lncRNAs are able to mediate transcription as well as DNA methylation of CpG island. 37 LncRNA H19 has been revealed to be capable of interacting with histone lysine methyltransferases. 38 Moreover, lncRNA H19 could bind to S-adenosylhomocysteine hydrolase (SAHH) and repressed its expression, thereby leading to DNMT3B, which produced methylate gene subsets. 39 It was reported that silencing of lncRNA H19 could elevate Nctc1 methylation which was mediated by DNMT3B. 40 Additionally, lncRNA H19 was found to be able to regulate expression of Hnf4α as well as its methylation. 41 In the current study, the ChIP assay showed that lncRNA H19 induced DNMT1 and DNMT3A to promote the methylation of CDH1; however, the potential mechanism implicated in link of LncRNA H19 with methyltransferases in lung adenocarcinoma cells still remained complicated.
To conclude, the present study demonstrated that silencing of lncRNA H19 inhibited EMT and proliferation while promoting apoptosis of lung adenocarcinoma cells via inhibition of methylation of CDH1 promoter (Figure 8 ), which may provide a novel molecular target for treatment of lung adenocarcinoma. However, the specific mechanism by which lncRNA H19 inhibits methylation of CDH1 promoter still lacks elucidation. Therefore, further study is required for validating our findings. In addition, we plan to supplement BSP experiment and to explore the relationship between lncRNA H19 and DNMT3B in the later experiment if possible.
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